Abbott Labs's most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $80.00 short put and a strike $75.00 long put offers a potential 20.19% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $80.00 by expiration. The full premium credit of $0.84 would be kept by the premium seller. The risk of $4.16 would be incurred if the stock dropped below the $75.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
Tue, 18 Jun 2019 21:50:09 +0000
Abbott (ABT) closed at $83.42 in the latest trading session, marking a +1.67% move from the prior day.
CARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings
Mon, 17 Jun 2019 16:00:00 +0000
ATLANTA and ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ — The global humanitarian organization CARE, the healthcare company Abbott (ABT) and its foundation the Abbott Fund today announced a three-year, $1 million program to screen, diagnose, prevent and manage noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Marawi City, Philippines. The partnership is among the first of its kind to address NCDs in areas affected by disasters, conflict and other humanitarian challenges.
Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
Mon, 17 Jun 2019 12:00:00 +0000
– Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation – Assay is the first and only rapid point-of-care …
Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
Mon, 17 Jun 2019 11:40:11 +0000
Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.
Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend
Fri, 14 Jun 2019 14:45:00 +0000
ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 382 nd consecutive quarterly …
Also on Market Tamer…
Follow Us on Facebook